Molecular Imaging

In a recent interview, Richard Duszak, MD, discussed new study findings that showed over nine percent annual increases in ultrasound, CT and MRI interpretation by office-based non-physician practitioners (NPPs) between 2013 and 2022.

Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.

In an interview, SNMMI president Cathy Cutler, PhD, discussed the impact of the recent CMS decision to unbundle reimbursement for diagnostic radiopharmaceuticals costing above $630 a day, calling it a “game changer” decision that will benefit patients, physicians, and the development of new radiopharmaceutical agents.

Catch up on the top radiology content of the past week.

In newly published guidelines, researchers discuss the utility of CT, MRI and PET/CT in the diagnosis, staging, treatment monitoring and follow-up imaging for peritoneal metastases in patients with ovarian or colorectal cancer.

Catch up on the top radiology content of the past week.

Designed for theranostic imaging applications, the AnyScan Trio SPECT/CT TheraMax scanner was recently unveiled at the annual meeting of the European Association of Nuclear Medicine (EANM).

Offering standardized assessment of amyloid plaque and insights on tau protein tangles, the newly clearly FDA features of Centiloid scoring and tau PET quantification with syngo.PET Cortical Analysis software may facilitate diagnosis of Alzheimer’s disease.

Catch up on the top radiology content of the past week.

Examining six comparative studies within a new meta-analysis, researchers found that FAPI PET/CT offered 11 percent higher pooled sensitivity and 28 percent higher pooled specificity than FDG PET/CT for diagnosing lymph node metastases in patients with lung cancer.

Catch up on the top radiology content of the past week.

Catch up on the top radiology content of the past week.

The clearance may facilitate improved standardization and efficiency of dosimetry-guided, theranostic applications of radiopharmaceutical therapy.

Catch up on the top radiology content of the past week.

Offering higher diagnostic efficacy than SPECT imaging for coronary artery disease (CAD) detection, the PET myocardial perfusion imaging agent Flyrcado™ (flurpiridaz F 18, GE HealthCare) provides unit dose availability and effectiveness in imaging patients with high BMI.

Catch up on the most-well viewed radiology content in September 2024.

Catch up on the most-well viewed prostate imaging content in September 2024.

Catch up on the top radiology content of the past week.

Now available with MIMneuro, the Centiloid scaling software provides automated quantitative assessment of amyloid plaque density, a key component of Alzheimer’s disease.

Catch up on the top radiology content of the past week.

Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.

The imaging agent 18F-FAPI PET/CT demonstrated greater than a 45 percent higher sensitivity rate in comparison to 18F-FDG PET/CT for the detection of axillary and extraaxillary regional lymph node metastases, according to a lesion-based analysis from a recent study.

Catch up on the most-well viewed radiology content in August 2024.

Targeting tau neurofibrillary tangles, the (18F)PI-2620 agent reportedly provides promising insight into the development of three neurodegenerative conditions including Alzheimer’s disease.

Catch up on the top radiology content of the past week.